Rivipansel (GMI-1070)

In 2011, Pfizer and GlycoMimetics entered into a worldwide license agreement for the development and, if approved by applicable regulatory authorities, commercialization of rivipansel. GlycoMimetics was responsible for development through the Phase 2 clinical trial and Pfizer is now responsible for all future clinical development of rivipansel. In June 2015, Pfizer announced that it had … Continue reading Rivipansel (GMI-1070)